Glycoengineering approaches generate new antibody variants with significantly enhanced capacity to recruit immune cells, like Natural Killer (NK) cells, macrophages/monocytes and neutrophils. By designing and controlling the type of sugar molecules in a specific region of the antibody, the affinity of the antibody for immune effector cells is increased. This allows more effective antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) and thus the capacity of a targeted antibody to trigger the death of cancerous cells. The first product based on the glycoengineering technology has recently entered the market.

Drawn to Science: the glycosylation of antibodies

Tags: Biotechnology